Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 10/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13360755 | 0.86 | KRAS (0.53) | KRASHDAC1HDAC6CNR1CNR2 | |
| SCHEMBL13360832 | 0.83 | KRAS (0.51) | KRASHDAC1HDAC6CNR1CNR2 | |
| SCHEMBL3310724 | 0.81 | CNR1 (0.70) | KRASHDAC1HDAC6CNR1CNR2 | |
| SCHEMBL13360756 | 0.79 | KRAS (0.47) | KRASHDAC1HDAC6CNR1CNR2 | |
| SCHEMBL13328924 | 0.79 | HTR6 (0.48) | HDAC1HDAC6 | |
| SCHEMBL3312822 | 0.78 | CNR1 (0.59) | KRASHDAC1HDAC6CNR1CNR2 | |
| SCHEMBL6422016 | 0.77 | HDAC1 (0.54) | KRASHDAC1HDAC6 | |
| SCHEMBL3083804 | 0.74 | PTGDR2 (0.68) | KRASHDAC1HDAC6AKR1B10AKR1B1 | |
| SCHEMBL3090435 | 0.73 | PTGDR2 (0.67) | KRASHDAC1HDAC6AKR1B10AKR1B1 | |
| SCHEMBL3085456 | 0.73 | KRAS (0.67) | KRASHDAC1HDAC6AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | CNR1, CNR2, OPRL1 | KRAS 1248/4885HDAC1 1291/4885HDAC6 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.